Literature DB >> 14737745

Soluble adhesion molecules in Finnish schoolchildren with signs of preclinical type 1 diabetes.

Anna Toivonen1, Petri Kulmala, Jukka Rahko, Jorma Ilonen, Mikael Knip.   

Abstract

BACKGROUND: We measured the circulating concentrations of the soluble forms of intercellular adhesion molecule-1, ICAM-1 (sCD54) and L-selectin (sCD62L) in 104 non-diabetic Finnish schoolchildren testing positive for one or more diabetes-associated autoantibodies and in 104 autoantibody-negative children to elucidate the relationship between soluble adhesion molecules and humoral, genetic and metabolic markers of preclinical type 1 diabetes.
METHODS: Specific enzyme-linked immunosorbent assays were used to analyse serum sICAM-1 and sL-selectin concentrations.
RESULTS: The sICAM-1 and sL-selectin levels were comparable in the autoantibody-positive and control children, even when comparing children with multiple autoantibodies with those having one or no autoantibodies. The IA-2A titres in children testing positive for this autoantibody correlated with the sICAM-1 concentrations (rs=0.62, P=0.05), but otherwise no significant associations were seen between the autoantibody specificities and the concentrations of soluble adhesion molecules. Control children with HLA DQB1 genotypes conferring a low or decreased risk of type 1 diabetes had higher levels of sL-selectin than those with high or moderate risk genotypes (P=0.04). sL-selectin concentrations were significantly increased in the autoantibody-positive children with a first-phase insulin response (FPIR) below the 5th (n=11;P=0.026) or 10th percentiles (n=17;P=0.009) relative to the children with a normal FPIR. No associations were observed between sICAM-1 concentrations and DQB1 genotypes or FPIR.
CONCLUSIONS: The data indicate that there are a few conspicuous signs of endothelial/leukocyte activation reflected in increased circulating levels of soluble adhesion molecules in schoolchildren who are positive for markers of preclinical type 1 diabetes. The correlation between sICAM-1 concentrations and IA-2A levels in the IA-2A-positive children suggests that the former may increase in late preclinical type 1 diabetes, as IA-2A are the last autoantibodies to appear in the prediabetic process. Increased sL-selectin concentrations in subjects with impaired beta-cell function may reflect an active destructive insulitis process. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14737745     DOI: 10.1002/dmrr.418

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

1.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

2.  Anti-inflammatory properties of C-Peptide.

Authors:  Jaime Haidet; Vincenza Cifarelli; Massimo Trucco; Patrizia Luppi
Journal:  Rev Diabet Stud       Date:  2009-11-10

3.  Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy.

Authors:  J Ma; A Möllsten; M Prázny; H Falhammar; K Brismar; G Dahlquist; S Efendic; H F Gu
Journal:  Diabet Med       Date:  2006-10       Impact factor: 4.359

4.  HLA, infections and inflammation in early stages of atherosclerosis in children with type 1 diabetes.

Authors:  Michal Odermarsky; Erkki Pesonen; Timo Sorsa; Åke Lernmark; Pirkko J Pussinen; Petru Liuba
Journal:  Acta Diabetol       Date:  2017-10-24       Impact factor: 4.280

5.  Abnormal Neutrophil Transcriptional Signature May Predict Newly Diagnosed Latent Autoimmune Diabetes in Adults of South China.

Authors:  Yixuan Xing; Qiuqiu Lin; Yue Tong; Wenzhi Zhou; Juan Huang; Yanfei Wang; Gan Huang; Yanhua Li; Zhongyuan Xiang; Zhiguang Zhou; Tian Li; Yang Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-18       Impact factor: 5.555

Review 6.  Neutrophils in type 1 diabetes.

Authors:  Juan Huang; Yang Xiao; Aimin Xu; Zhiguang Zhou
Journal:  J Diabetes Investig       Date:  2016-02-01       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.